Effectiveness and Safety of Septum-guided Segmentectomy in Solid-dominant, Deep-seated Early-stage Non-small Cell Lung Cancer (≤2 cm): A Single-center, Prospective, Single-arm Clinical Trial
The purpose of this study is to evaluate the safety and effectiveness of a specialized surgical technique called Septum-guided Segmentectomy for treating early-stage lung cancer located deep within the lung tissue.Standard surgery for lung cancer often involves removing an entire lung lobe (lobectomy), which can significantly reduce a patient's breathing capacity. For small tumors, removing only a segment of the lung (segmentectomy) can preserve more healthy tissue. However, for tumors located deep in the lung, traditional segmentectomy is technically challenging and risks leaving cancer cells behind.In this study, surgeons will use the natural anatomical boundaries-the intersegmental veins and their surrounding thin membranes (septa)-as a guide to precisely remove the target lung segment. This septum-guided approach aims to ensure the cancer is completely removed while maximizing the preservation of healthy lung function.Participants will be followed for 3 years after surgery to monitor for cancer recurrence and assess their long-term recovery.
• Age 18-80 years
• Clinical stage IA (cT1a-bN0M0)
• tumor diameter ≤ 2 cm
• Pathological feature: Solid-dominant lesion (CTR \> 0.5)
• Tumor location: Deep-seated within the lung parenchyma (inner 2/3), defined as the tumor center being located in the inner 2/3 region of the lung field on axial, coronal, and sagittal CT views
• ECOG Performance Status: 0-1
• Pulmonary function: FEV1 ≥ 60% predicted and DLCO SB ≥ 60% predicted
• Participants must be willing and able to provide written informed consent